Canakinumab MAP in COVID-19 Pneumonia With CRS

NCT04476706 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Cytokine Release Syndrome in COVID-19-induced Pneumonia

Interventions

DRUG: canakinumab

Sponsor

Novartis Pharmaceuticals